Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03219047 · ClinicalTrials.gov registry record · Early Phase 1
Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT03219047: Completed Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03219047 is a Early Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03219047, a Early Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This early phase I pilot trial studies how well patient-derived xenografts work in personalizing treatment for patients with mantle cell lymphoma that has come back (relapsed) or that isn't responding to treatment (refractory). Xenograft models involve taking a piece of tissue from a tumor that was previously collected and putting that tissue inside of a mouse in the laboratory. This allows the tumor to grow in the mouse so that researchers can test the effects of certain drugs. If the drugs have an effect on the tumor(s) in the mice, patients may receive that treatment for mantle cell lymphoma.
Interventions
- OTHER Best Practice
- DRUG Ibrutinib
- OTHER Patient Derived Xenograft
- OTHER Personalized Medicine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2023-07-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03219047
The ClinicalTrials.gov registry entry for NCT03219047 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Best Practice is the first listed.
NCT03219047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03219047 about?
NCT03219047 is a clinical study titled "Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma". This early phase I pilot trial studies how well patient-derived xenografts work in personalizing treatment for patients with mantle cell lymphoma that has come back (relapsed) or that isn't responding to treatment (refractory). Xenograft models involve taking a piece of tissue from a tumor that was ...
What is the current status of trial NCT03219047?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2018-12-20. Estimated completion is 2023-07-03.
What interventions are being tested in trial NCT03219047?
The interventions under investigation include: Best Practice (OTHER), Ibrutinib (DRUG), Patient Derived Xenograft (OTHER), Personalized Medicine (OTHER).
Who is sponsoring clinical trial NCT03219047?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.